Format

Send to:

Choose Destination
See comment in PubMed Commons below
Handb Clin Neurol. 2013;115:415-27. doi: 10.1016/B978-0-444-52902-2.00023-0.

Treatment of chronic inflammatory demyelinating polyradiculoneuropathy.

Author information

  • 1Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany. Electronic address: hans-peter.hartung@uni-duesseldorf.de.

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a sporadically occurring, acquired neuropathic condition of autoimmune origin with chronic progressive or relapsing-remitting disease course. CIDP is a treatable disorder; a variety of immunosuppressive and immunomodulatory agents are available to modify, impede, and even reverse the neurological deficits and sequelae that manifest in the course of the disease. However, in many cases CIDP is not curable. Challenges that remain in the treatment of CIDP patients are well recognized and include a remarkably individual heterogeneity in terms of disease course and treatment response as well as a lack of objective and feasible measures to predict and monitor the responsiveness to the available therapies. In this chapter an overview of the currently used drugs in the treatment of CIDP patients is given and some important and controversial issues that arise in the context of care for CIDP patients are discussed.

Copyright © 2013 Elsevier B.V. All rights reserved.

KEYWORDS:

B cells; CIDP; IVIg; T cells; animal model; autoantibodies; complement; immunomodulatory agents; pathogenesis

PMID:
23931793
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk